Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Akademin, University of Gothenburg, Gothenburg, Sweden.
Acta Obstet Gynecol Scand. 2024 Jan;103(1):13-29. doi: 10.1111/aogs.14706. Epub 2023 Oct 27.
Hyperemesis gravidarum affects 0.3%-3% of pregnant women each year and is the leading cause of hospitalization in early pregnancy. Previous systematic reviews of available treatments have found a lack of consistent evidence, and few studies of high quality. Since 2016, no systematic review has been conducted and an up-to date review is requested. In a recent James Lind Alliance collaboration, it was clear that research on effective treatments is a high priority for both patients and clinicians.
Searches without time limits were performed in the AMED, CINAHL, Cochrane Library, EMBASE, Medline, PsycINFO, and Scopus databases until June 26, 2023. Studies published before October 1, 2014 were identified from the review by O'Donnell et al., 2016. Selection criteria were randomized clinical trials and non-randomized studies of interventions comparing treatment of hyperemesis gravidarum with another treatment or placebo. Outcome variables included were: degree of nausea; vomiting; inability to tolerate oral fluids or food; hospital treatment; health-related quality of life, small-for-gestational-age infant; and preterm birth. Abstracts and full texts were screened, and risk of bias of the studies was assessed independently by two authors. Synthesis without meta-analysis was performed, and certainty of evidence was assessed using the GRADE approach. PROSPERO (CRD42022303150).
Twenty treatments were included in 25 studies with low or moderate risk of bias. The certainty of evidence was very low for all treatments except for acupressure in addition to standard care, which showed a possible moderate decrease in nausea and vomiting, with low certainty of evidence.
Several scientific knowledge gaps were identified. Studies on treatments for hyperemesis gravidarum are few, and the certainty of evidence for different treatments is either low or very low. To establish more robust evidence, it is essential to use validated scoring systems, the recently established diagnostic criteria, clear descriptions and measurements of core outcomes and to perform larger studies.
妊娠剧吐每年影响 0.3%-3%的孕妇,是早孕住院的主要原因。以前对现有治疗方法的系统评价发现缺乏一致的证据,高质量的研究很少。自 2016 年以来,尚无系统评价,因此需要进行最新的综述。在最近的詹姆斯·林德联盟合作中,很明显,针对有效治疗方法的研究是患者和临床医生的高度优先事项。
无时间限制地在 AMED、CINAHL、Cochrane 图书馆、EMBASE、Medline、PsycINFO 和 Scopus 数据库中进行了检索,检索时间截至 2023 年 6 月 26 日。2016 年 O'Donnell 等人的综述中确定了 2014 年 10 月 1 日之前发表的研究。选择标准为比较治疗妊娠剧吐的干预措施与另一种治疗或安慰剂的随机临床试验和非随机研究。纳入的结局变量包括:恶心程度;呕吐;无法耐受口服液体或食物;住院治疗;健康相关生活质量;小于胎龄儿;和早产。筛选摘要和全文,由两位作者独立评估研究的偏倚风险。未进行荟萃分析的综合分析,并使用 GRADE 方法评估证据的确定性。PROSPERO(CRD42022303150)。
25 项研究中有 20 种治疗方法,其偏倚风险较低或中等。除了标准治疗外加用穴位按压外,所有治疗方法的证据确定性均非常低,仅可能中度减轻恶心和呕吐,证据确定性低。
确定了几个科学知识空白。妊娠剧吐的治疗研究很少,不同治疗方法的证据确定性要么很低,要么非常低。为了建立更可靠的证据,必须使用经过验证的评分系统、最近建立的诊断标准、明确描述和测量核心结局,并进行更大规模的研究。